Effects of early palliative care integration on patients with newly diagnosed multiple myeloma.

Abstract

While numerous studies underscore the benefits of early palliative care (EPC) for patients with solid tumors, its effects on patients with multiple myeloma (MM) are not as widely known. This study aims to determine the effects of EPC integration on patients with newly diagnosed symptomatic MM and the feasibility of this approach. This prospective cohort study enrolled patients within eight weeks of diagnosis. Participants met with a palliative care team monthly for 12months. Functional Assessment of Cancer Therapy-General (FACT-G) plus Multiple Myeloma Subscale (FACT-MM), and Hospital Anxiety and Depression Scale (HADS) were administered upon enrollment and every three months. Proportion of completed visits and assessments determined the feasibility of EPC. Of the twenty participants enrolled from January 2020 to November 2022, median age was 65 (range 40, 77), 15 (75%) were female, 15 (75%) were white, 65% completed assessments at six months, and 60% at 12months. The following measures significantly improved at 12months versus baseline: FACT-G scoresincreased by 15.1 points (adjusted 95% CI: 2.2-28.1, adjusted p = 0.02); Functional Well-Being scores increased by 6.0 points (adjusted 95% CI: 1.1-10.9, adjusted p = 0.01); and Pain Subscale scores increased by 3.4 points (adjusted 95% CI: 0.5-6.4, adjusted p = 0.02). Depression and anxiety scores did not significantly change over time. Functional well-being, pain experience and overall QOL improved in a cohort of patients with newly diagnosed MM after 12months of EPC involvement. Although monthly visits seemed feasible, the findings suggest thatfurther researchis needed to explore the optimal timing of palliative care interventionsin the MM trajectory. ClinicalTrials.gov ID NCT04248244 (Registration Date: January 30, 2020).